Latest news with #DyneTherapeutics
Yahoo
5 days ago
- Health
- Yahoo
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it will be presenting new preclinical data demonstrating the potential of DYNE-302 to achieve functional improvement in facioscapulohumeral muscular dystrophy (FSHD). The data will be presented at the 32nd Annual FSHD Society's International Research Congress being held June 12-13, 2025, in Amsterdam. In a mouse model of severe FSHD, a single intravenous dose of DYNE-302 administered at the peak of muscle weakness restored ability to run on a treadmill. Analysis of gene activity in skeletal muscle indicated correction of muscle damage and inflammation. These findings suggest that preexisting and severe skeletal muscle disease in FSHD has the potential to be reversed by targeting the DUX4 mRNA with DYNE-302. FSHD is a rare, progressive, inherited muscle disease. De-repression of DUX4 in skeletal muscle drives disease pathogenesis, leading to muscle damage and loss of function. This results in a range of symptoms that restrict daily activities and have a high physical, emotional, and financial burden. DYNE-302 leverages a TfR1-targeting Fab for muscle delivery of an siRNA payload highly specific for DUX4 mRNA with the aim of suppressing DUX4 expression and the downstream DUX4 transcriptome. Oral Presentation: DYNE-302 leads to functional improvement and resolves muscle transcriptomic changes in mouse models of FSHDSession: Mechanisms of Disease & Interventional StrategiesDate/Time: Friday, June 13, 2025, at 12:00 p.m. CEST / 6:00 a.m. Stefano Zanotti, PhD, Head of Neuromuscular Research, Dyne The presentation will also be available in the Scientific Publications & Presentations section of Dyne's website following the session. About Facioscapulohumeral Muscular Dystrophy (FSHD) FSHD is a rare, progressive, genetic disease caused by a mutation in the DUX4 gene, leading to skeletal muscle loss, muscle weakness and wasting. Individuals with FSHD carry a genetic mutation that allows the DUX4 gene to be sporadically activated in muscle cells, causing their gradual destruction throughout the body. People living with FSHD experience weakness in all major muscle groups throughout the body and limited mobility. An estimated 16,000 to 38,000 individuals in the United States and approximately 35,000 in Europe are affected by FSHD, but there are currently no approved therapies. About Dyne Therapeutics Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit and follow us on X, LinkedIn and Facebook. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the potential of DYNE-302, and the sufficiency of Dyne's cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and as to the regulatory approval process for Dyne's product candidates; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the company's most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release. Contacts: InvestorsMia Tobiasir@ MediaStacy Nartkersnartker@ in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
Antibody Conjugate Oligonucleotide Market Analysis and Forecast, 2025-2035: CRISPR/Cas9 Integration with Oligonucleotide Conjugates Opens New Avenues in Gene Therapy
The global antibody conjugate oligonucleotide market is on track for significant growth, driven by increased demand for targeted therapies in oncology, autoimmune diseases, and genetic disorders, along with advances in genetic medicine. By 2035, the market is projected to expand exponentially due to the rise of oligonucleotide-based therapies and innovation in gene editing technologies. Key players like Avidity Biosciences and AstraZeneca are leading advancements, particularly in North America, with strategic collaborations and investments. However, high development costs remain a challenge. Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Antibody Conjugate Oligonucleotide Market - A Global and Regional Analysis: Focus on Type, Oligonucleotide Type, Target Disease, and Country Analysis - Analysis and Forecast, 2025-2035" has been added to offering. The global antibody conjugate oligonucleotide market is positioned for significant expansion, propelled by increasing demand for targeted therapies and advancements in genetic medicine. The market is expected to grow in 2024 as research into monoclonal antibody-oligonucleotide conjugates intensifies, especially in fields like oncology, autoimmune diseases, and genetic disorders. By 2035, the market could experience exponential growth, driven by the adoption of oligonucleotide-based therapies and advances in genomic technologies, including small interfering RNA (siRNA) and antisense oligonucleotides. The prevalence of cancer and genetic disorders remains a crucial driver. The World Health Organization (WHO) estimates 18 million new cancer cases and 9.6 million deaths annually, emphasizing the need for effective targeted therapies. Companies like Ionis Pharmaceuticals demonstrate promising results with antisense oligonucleotide therapy for spinal muscular atrophy. Similarly, there's a rise in genetic disorders such as Duchenne muscular dystrophy and cystic fibrosis, increasing demand for therapies targeting the genetic causes of these diseases. Integrating oligonucleotide conjugates with gene editing technologies like CRISPR/Cas9 is expected to propel market growth further. This fusion not only facilitates precise genetic material delivery but also targeted gene modification. Avidity Biosciences and Editas Medicine are pioneering this integration to enhance genetic therapies' delivery and efficacy, opening new possibilities for treating gene-based diseases. One key opportunity lies in the rapid growth of personalized medicine. Genetic profiling and biomarker identification are enabling companies to develop therapies tailored to individual patients, particularly in oncology and rare genetic disorders. Dyne Therapeutics and Tallac Therapeutics are at the cutting edge of this personalized approach, crafting targeted therapies for previously untreatable conditions. However, high development and production costs pose a challenge, particularly restricting accessibility in low-income regions. Substantial capital investment in research, development, and specialized infrastructure remains a barrier to broader adoption. Leading companies in the market, including Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, and AstraZeneca, are leveraging innovation, strategic collaborations, acquisitions, and expansion into new therapeutic areas to boost competitiveness. Dyne's Dyn101, for example, focuses on improved muscle delivery for Duchenne muscular dystrophy therapy. Market Segmentation: Monoclonal antibody-oligonucleotide conjugates are leading due to their ability to provide precise therapies for complex diseases. Companies like Avidity Biosciences are advancing treatments such as AOC 1001 for Duchenne muscular dystrophy, demonstrating the technology's adoption in developing targeted therapies for rare diseases. North America to Lead the Market North America dominates the market owing to a robust biotech ecosystem and substantial R&D investments. Key players like AstraZeneca and Ionis Pharmaceuticals are advancing gene-based treatments, with Ionis achieving a milestone in gene therapy with Spinraza for spinal muscular atrophy. Additionally, AstraZeneca's collaboration with Ionis in oncology underscores the region's investment in biotechnology, supported by favorable regulatory environments and FDA's expedited approval processes, fostering the growth of oligonucleotide conjugate therapies. Key Topics Covered: 1. Global Antibody Conjugate Oligonucleotide Market Outlook2. Global Antibody Conjugate Oligonucleotide Market: Industry Analysis3. Global Antibody Conjugate Oligonucleotide Market (by Type)4. Global Antibody Conjugate Oligonucleotide Market (by Oligonucleotide Type)5. Global Antibody Conjugate Oligonucleotide Market (by Target Disease)6. Global Antibody Conjugate Oligonucleotide Market (by Region)7. Global Antibody Conjugate Oligonucleotide Market: Competitive Insights and Company Profiles AstraZeneca Avidity Biosciences Dyne Therapeutics Tallac Therapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
15-04-2025
- Business
- Yahoo
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
Vikram Ranade, PhD Ranjan Batra, PhD Oxana Beskrovnaya, PhD - Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointments of Vikram (Vik) Ranade, PhD, as chief business officer (CBO) and Ranjan (Ron) Batra, PhD, as chief scientific officer (CSO) of Dyne. Dr. Ranade will lead business development, corporate strategy and strategic partnerships to support the company's late-stage clinical and commercialization plans. Dr. Batra will lead the company's research strategy, pipeline development and activities supporting clinical development. Effective April 28, 2025, Oxana Beskrovnaya, PhD, will transition from CSO to chief innovation officer (CIO) responsible for driving Dyne's comprehensive innovation strategy to maximize the value of its FORCE™ platform and further enable the company's long-term success. 'I am excited to welcome Vik and Ron to our leadership team. Vik's experience in business development and corporate strategy will be invaluable as we prepare for the potential launches of two medicines in 2027 in myotonic dystrophy type 1 and Duchenne muscular dystrophy. Our incoming CSO, Ron, will play a key role in advancing our pipeline and elucidating the power of the FORCE platform to deliver functional improvement in the clinic,' said John Cox, president and chief executive officer of Dyne. 'With the addition of Vik, Ron and our CFO, Erick Lucera, as well as Oxana in her new role as CIO, we are well positioned to drive the business, deliver therapies that bring functional improvement to patients and create significant shareholder value through our clinical programs, pipeline and unique platform.' Dr. Ranade joins Dyne, effective immediately, from Tessera Therapeutics, where he was senior vice president of corporate development, leading strategy and business development, and was member of the executive team. During more than five years at Tessera he also played a key role in equity financings totaling more than $600 million. Previously, he worked in McKinsey & Company's healthcare practice, advising biopharmaceutical and biotechnology companies on strategy, M&A and R&D. He led diligence on completed deals with an aggregate transaction value of more than $15 billion and advised on clinical strategy for more than 20 programs. Dr. Ranade also co-led McKinsey's Center for Asset Optimization, which focuses on clinical-stage asset development strategy. Dr. Ranade holds a PhD in Genetics and Development from Columbia University and a BS in biochemistry from Brandeis University, where he earned highest honors for his research on DNA damage repair pathways. 'I am thrilled to welcome Ron as our new scientific leader. He brings outstanding scientific expertise and the required peer network and passion to continue to expand Dyne's pipeline of potentially transformative therapies,' said Dr. Beskrovnaya. 'In my new role, I look forward to working with our strong leadership team and leveraging our world-class expertise in TfR1 delivery to pioneer and accelerate new therapeutic applications.' Dr. Batra joins Dyne, effective April 28, 2025, from Lexeo Therapeutics, where he was vice president of research and translation. A leading expert in RNA biology and therapeutics, he has developed cutting-edge treatments for genetic diseases. Previously, Dr. Batra served as a senior vice president of R&D at LocanaBio, advancing RNA-targeted therapies for rare disorders including Duchenne muscular dystrophy and myotonic dystrophy. Prior to LocanaBio, he worked at Verily Life Sciences and conducted pioneering research at UC San Diego and the University of Florida with more than 35 publications and patents. Dr. Batra earned a PhD in genetics from the University of Florida, where he studied RNA biology and gene therapy for neuromuscular diseases. About Dyne TherapeuticsDyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit and follow us on X, LinkedIn and Facebook. Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the potential of DYNE-101 and DYNE-251, and expectations regarding the timing of commercial launches constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and as to the regulatory approval process for Dyne's product candidates; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-K and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release. Contacts: InvestorsMia Tobiasir@ Nartkersnartker@ Photos accompanying this announcement are available at: in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J. Lucera. The awards were approved by the Compensation Committee of Dyne and made as an inducement material to Mr. Lucera's acceptance of employment with Dyne under Dyne's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted to Mr. Lucera effective as of March 31, 2025 and consists of a non-statutory stock option to purchase up to 214,500 shares of Dyne's common stock at a per share exercise price equal to the closing price of Dyne's common stock on The Nasdaq Global Select Market on March 31, 2025, and a restricted stock unit award with respect to 66,100 shares of Dyne's common stock. The stock option award has a ten-year term and is scheduled to vest over four years, with 25% of the original number of shares vesting on March 31, 2026 and the remainder vesting in equal quarterly installments over the three years thereafter, subject to Mr. Lucera's continued service to Dyne through the applicable vesting dates. The restricted stock unit award is scheduled to vest in equal annual installments over four years with the first installment vesting on March 31, 2026, subject to Mr. Lucera's continued service to Dyne through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Dyne's 2024 Inducement Stock Incentive Plan. About Dyne Therapeutics Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit and follow us on X, LinkedIn and Facebook. Contacts: InvestorsMia Tobiasir@ MediaStacy Nartkersnartker@ in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Erick J. Lucera - Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointment of Erick J. Lucera, as chief financial officer (CFO) of Dyne, effective March 31, 2025. Mr. Lucera brings more than thirty years of financial, operational and investment experience in the life science industry to Dyne and will be instrumental in helping the company advance two late-stage clinical programs toward potential regulatory approvals. 'Erick's deep industry expertise and extensive track record in financial strategy, efficient capital allocation and operations make him a vital addition to our team,' said John Cox, president and chief executive officer of Dyne. 'His leadership will be critical as we prepare for the potential expedited approvals and commercialization of our DM1 and DMD programs.' 'I am deeply impressed by Dyne's platform, and its ability to execute on its goals to rapidly advance clinical programs,' said Mr. Lucera. 'With two highly promising late-stage clinical assets and a strong pipeline, the company is poised to create significant value for both patients and shareholders. It's exciting to join Dyne at this pivotal moment, and I look forward to applying my experience to help Dyne effectively deliver on all of the valuable opportunities ahead.' Erick joins Dyne from Editas Medicine, where he served as CFO, overseeing financial strategy, financing initiatives, strategic licensing transactions and infrastructure scaling to prepare the company for commercialization. Previously, as CFO of AVEO Pharmaceuticals, he led its transition from a clinical-stage company to commercialization, drove R&D pipeline growth and played a key role in its acquisition by LG Chem. Before that, he was CFO, treasurer, and secretary at Valeritas, where he helped develop the company's global distribution strategy. Prior to Valeritas, Erick was CFO, treasurer, and secretary at Viventia Bio, where he prepared the company for an initial public offering. Erick also served as Vice President of corporate development at Aratana Therapeutics, securing multiple financings and managing licensing transactions and acquisitions to strengthen the company's pipeline. Earlier in his career, he spent 15 years in investment management as a healthcare analyst. He holds a Certificate in Public Health from Harvard University, an MS in finance from Boston College, an MBA from Indiana University and a BS in accounting from the University of Delaware. About Dyne Therapeutics Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit and follow us on X, LinkedIn and Facebook. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, and the potential of DYNE-101 and DYNE-251, and the availability of expedited approval pathways constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and as to the regulatory approval process for Dyne's product candidates; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-K and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release. Contacts: InvestorsMia Tobiasir@ MediaStacy Nartkersnartker@ A photo accompanying this announcement is available at in to access your portfolio
